Yamabuki King Lion's Mane (Hericium erinaceus 'Yamabuki King')

Yamabuki King is a cultivated strain of Hericium erinaceus selected for potentially elevated concentrations of hericenones and erinacines, bioactive compounds that stimulate nerve growth factor (NGF) synthesis in neuronal tissue. These terpenoid and aromatic compounds act on TrkA receptors and downstream MAPK/ERK signaling pathways, making this strain of particular interest in preclinical neurotrophin research.

Origin & History

Yamabuki King Lion's Mane is a cultivar variant of Hericium erinaceus, a mushroom native to temperate regions of the Northern Hemisphere, particularly Eastern Asia. It is produced from fruiting bodies or mycelium using extraction methods such as hot water for polysaccharides, ethanol for hericenones and erinacines, or methanol for diverse metabolites.

Historical & Cultural Context

In Eastern Asian traditional medicine, particularly Chinese and Japanese practices, H. erinaceus (yamabushitake) has been used for centuries both culinarily and medicinally to improve memory and digestion. It is characterized by a sweet taste and mild properties in traditional preparations.

Health Benefits

• Potential neuroprotection through nerve growth factor (NGF) promotion (preliminary evidence from in-vitro studies only)
• May support neuronal survival via hericenones and erinacines compounds (preclinical evidence only)
• Possible immunomodulatory activity from HEP-W polysaccharides (preliminary evidence)
• Traditional use for memory support (historical use only, no clinical validation)
• Traditional digestive health support (historical use only, no clinical validation)

How It Works

Erinacines (diterpenoids found in the mycelium) cross the blood-brain barrier and upregulate NGF mRNA expression, activating TrkA receptors and triggering the MAPK/ERK and PI3K/Akt signaling cascades that promote neuronal survival and differentiation. Hericenones (aromatic compounds concentrated in the fruiting body) independently stimulate NGF secretion from 1321N1 astrocytoma cells in vitro. The HEP-W beta-glucan polysaccharides modulate immune activity by binding Dectin-1 receptors on macrophages and dendritic cells, promoting cytokine release including TNF-alpha and IL-6.

Scientific Research

No human clinical trials, RCTs, or meta-analyses were found specifically for the Yamabuki King cultivar. Available research pertains only to standard H. erinaceus with preclinical neuroprotection studies showing hericenones and erinacines promoting neuronal survival in vitro, but human data is limited.

Clinical Summary

No clinical trials have been conducted specifically on the Yamabuki King cultivar; available evidence derives from studies on Hericium erinaceus broadly and must be interpreted with caution when applied to this strain. The most cited human trial (Mori et al., 2009, n=30) found that 3g/day of H. erinaceus powder over 16 weeks significantly improved Hasegawa Dementia Scale scores in mild cognitive impairment patients, with benefits reversing after discontinuation. A 2023 randomized trial (n=41) using 1.8g/day of H. erinaceus extract over 12 weeks demonstrated improvements in stress and sleep quality metrics versus placebo. No strain-specific pharmacokinetic or efficacy data exist for Yamabuki King, so all neurological benefit claims remain preliminary and extrapolated from general H. erinaceus research.

Nutritional Profile

Yamabuki King is a cultivated variety of Hericium erinaceus with nutritional composition broadly consistent with the species, though variety-specific quantitative data is limited. General H. erinaceus nutritional profile per 100g dry weight: Protein: 20–30g (containing all essential amino acids; glutamic acid, aspartic acid, and leucine predominant); Fat: 3–5g (primarily linoleic acid and oleic acid); Carbohydrates: 50–60g total; Dietary fiber: 15–25g (including beta-glucans estimated at 3–5g/100g dry weight, primarily β-1,3/1,6-glucan linkages); Ash/minerals: 6–10g. Key minerals: Potassium (~3,000–4,500mg/100g dry), Phosphorus (~900–1,200mg/100g dry), Zinc (~5–8mg/100g dry), Iron (~4–7mg/100g dry), Calcium (~20–40mg/100g dry), Magnesium (~100–200mg/100g dry). Vitamins: Ergosterol (provitamin D2 precursor): ~100–400mg/100g dry weight (converts to vitamin D2 upon UV exposure); B-vitamins present including thiamine, riboflavin, niacin, and B6 in modest amounts. Bioactive compounds: Hericenones (A–H, primarily in fruiting body): estimated 0.05–0.5mg/g dry weight; Erinacines (A–K, primarily in mycelium): 0.1–1.0mg/g dry weight; HEP polysaccharides: variable by extraction method. Yamabuki King phenotypically produces larger, denser fruiting bodies with reported higher polysaccharide content versus wild types, but no peer-reviewed variety-specific quantification is published. Bioavailability note: Raw consumption reduces bioavailability of polysaccharides and hericenones; cooking or hot-water extraction significantly improves polysaccharide solubility and absorption. Erinacines show better extraction via ethanol/methanol solvents.

Preparation & Dosage

No clinically studied dosage ranges are available for Yamabuki King or standardized H. erinaceus in human trials. Preclinical contexts mention erinacine A at 5 mg/g dry mycelium weight, but no human dosages for extracts or powders have been established. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

NGF-supporting compounds, neuroprotective antioxidants, cognitive nootropics, adaptogenic mushrooms, omega-3 fatty acids

Safety & Interactions

Hericium erinaceus, including cultivated strains like Yamabuki King, is generally well-tolerated; the most commonly reported adverse effects are mild gastrointestinal discomfort and, in rare cases, skin rash or respiratory irritation potentially indicating allergic sensitization. Individuals with mushroom allergies or known mold sensitivities should exercise caution and consult a healthcare provider before use. Due to preliminary immunomodulatory activity via beta-glucan pathways, caution is warranted in individuals on immunosuppressant medications such as cyclosporine or tacrolimus, as additive or antagonistic effects are theoretically possible though unstudied. Safety data in pregnancy and lactation are absent, and use is not recommended in these populations until adequate evidence is available.